NASDAQ : CABA
Cabaletta Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 256.01M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 241.60M |
| Enterprise Value | 42.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 169.55M |
| Shares Outstanding | 169.55M |
| Shares Change (YoY) | +121.83% |
| Shares Change (QoQ) | +34.93% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 80.10% |
| Float | 141.48M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.20 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.79 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -80.94 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -93.20% |
| Return on Assets (ROA) | -48.19% |
| Return on Invested Capital (ROIC) | -52.74% |
| Return on Capital Employed (ROCE) | -85.56% |
| Weighted Average Cost of Capital (WACC) | 21.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 158 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.47 |
| 52-Week Price Change | -60.25% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 2.85 |
| Relative Strength Index (RSI) | 34.64 |
| Average Volume (20 Days) | 4,674,139 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 39.29M |
| Short Previous Month | 38.61M |
| Short % of Shares Out | 23.17% |
| Short % of Float | 27.77% |
| Short Ratio (days to cover) | 6.67 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -185.52M |
| Pretax Income | -181.32M |
| Net Income | -181.32M |
| EBITDA | -184.12M |
| EBIT | -185.52M |
| Earnings Per Share (EPS) | -$1.54 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 225.10M |
| Total Debt | 25.71M |
| Net Cash | 199.39M |
| Net Cash Per Share | $1.18 |
| Equity (Book Value) | 210.59M |
| Book Value Per Share | 1.26 |
| Working Capital | 191.12M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -153.93M |
| Capital Expenditures | -283,000 |
| Depreciation & Amortization | 1.40M |
| Net Borrowing | -9.80M |
| Free Cash Flow | -154.21M |
| FCF Per Share | -$0.91 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -121.83% |
| Shareholder Yield | -121.83% |
| Earnings Yield | -108.21% |
| FCF Yield | -60.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.25 |
| Price Target Difference | 829.83% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |